---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-26-012435"
form_type: "8-K"
ticker: "GOVX"
cik: "0000832489"
company_name: "GeoVax Labs, Inc."
filed_at: "2026-04-15T23:59:59+00:00"
generated_at: "2026-05-15T06:16:51.661401+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# GeoVax reports 2025 net loss $21.5M; Phase 3 trial for mpox vaccine planned H2 2026

## Summary
- Net loss $21.5M ($22.40/share) vs $25.0M ($120.46/share) in 2024; revenue $2.5M from BARDA contract.
- Cash $3.1M at Dec 31, 2025; R&D expenses $18.1M (down from $23.7M); BARDA contract terminated Apr 2025.
- GEO-MVA Phase 3 trial to start H2 2026; EMA supports streamlined development without Phase 1/2.
- GEO-CM04S1 COVID vaccine Phase 2 data in 2026; Gedeptin oncology Phase 2 planned for 2027.

## SEC filing metadata
- accession: 0001437749-26-012435
- form_type: 8-K
- ticker: GOVX
- cik: 0000832489
- company_name: GeoVax Labs, Inc.
- filed_at: 2026-04-15T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/832489/000143774926012435/0001437749-26-012435-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/832489/000143774926012435/govx20260415_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-26-012435
- JSON: https://secwatch.observer/filing/0001437749-26-012435.json
- Plain text: https://secwatch.observer/filing/0001437749-26-012435.txt

## Key facts
- Earnings Releases
  GeoVax Labs, Inc. reported the year ended December 31, 2025 results: revenue $2.5 million, net income $21.5 million, EPS $22.40 per share.
  - Period: the year ended December 31, 2025
  - Revenue: $2.5 million
  - Net income: $21.5 million
  - EPS: $22.40 per share
  - Result: reported results
  source text: Net loss for the year ended December 31, 2025, was $21.5 million, or $22.40 per share, as compared to $25.0 million, or $120.46 per share, for the year ended December 31, 2024. Revenue : For the year ended December 31, 2025, the Company reported $2.5 million of government contract revenues associated with the BARDA/RRPV Project NextGen award, compared to $4.0 million during 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/832489/000143774926012435/0001437749-26-012435-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.